Oxygen control in bioreactor drives high yield production of functional hiPSC-like hepatocytes for advanced liver disease modelling
Hepatocytes-like cells (HLC) derived from human induced pluripotent stem cells show great promise for cell-based liver therapies and disease modelling. However, their application is currently hindered by the low production yields of existing protocols. We aim to develop a bioprocess able to generate high numbers of HLC. We used stirred-tank bioreactors with a rational control of dissolved oxygen concentration (DO) for the optimization of HLC production as 3D aggregates. We evaluated the impact of controlling DO at physiological levels (4%O<sub>2</sub>) during hepatic progenitors' stage on cell proliferation and differentiation efficiency. Whole transcriptome analysis and biochemical assays were performed to provide a detailed characterization of HLC quality attributes. When DO was controlled at 4%O<sub>2</sub> during the hepatic progenitors' stage, cells presented an upregulation of genes associated with hypoxia-inducible factor pathway and a downregulation of oxidative stress genes. This condition promoted higher HLC production (maximum cell concentration: 2 × 10<sup>6</sup> cell/mL) and improved differentiation efficiencies (80% Albumin-positive cells) when compared to the bioreactor operated under atmospheric oxygen levels (21%O<sub>2</sub>, 0.6 × 10<sup>6</sup> cell/mL, 43% Albumin positive cells). These HLC exhibited functional characteristics of hepatocytes: capacity to metabolize drugs, ability to synthesize hepatic metabolites, and inducible cytochrome P450 activity. Bioprocess robustness was confirmed with HLC derived from different donors, including a primary hyperoxaluria type 1 (PH1) patient. The generated PH1.HLC showed metabolic features of PH1 disease with higher secretion of oxalate compared with HLC generated from healthy individuals. This work reports a reproducible bioprocess, that shows the importance of controlling DO at physiological levels to increase HLC production, and the HLC capability to display PH1 disease features.
Authors
- Juan R. Rodríguez-Madoz (ORCID: https://orcid.org/0000-0003-4327-1866)
- María Eréndira Calleja-Cervantes (ORCID: https://orcid.org/0000-0003-0688-0793)
- Felipe Prósper (ORCID: https://orcid.org/0000-0001-6115-8790)
- Joana I. Almeida (ORCID: https://orcid.org/0000-0003-0131-4258)
- Margarida Serra (ORCID: https://orcid.org/0000-0001-5013-6625)
- Paula M. Alves (ORCID: https://orcid.org/0000-0003-1445-3556)
- Isabel Crespo
- Nikolaus Virgolini
- Pedro Vicente (ORCID: https://orcid.org/0000-0003-2091-4347)
- Inês A. Isidro
Institutions
- Clinica Universidad de Navarra (ES)
- Instituto de Investigación Sanitaria Aragón (ES)
- Centro de Investigación Biomédica en Red de Cáncer (ES)
- Instituto de Biologia Experimental e Tecnológica (PT)
- Universidade Nova de Lisboa (PT)
- Universidad de Navarra (ES)
Publication Details
- Journal
- Scientific Reports
- Published
- 2024-10-19
- DOI
- https://doi.org/10.1038/s41598-024-75582-z
- Citations
- 8
- Primary Topic
- Liver physiology and pathology
- Type
- article
- Field-Weighted Citation Impact
- 2.96
Funders
- E-Rare
- Ministério da Ciência, Tecnologia e Ensino Superior
- Horizon 2020 Framework Programme
- Fundação para a Ciência e a Tecnologia